Crystagen
What is it?
Crystagen is a named peptide product in the institute reports, described using glutamic acid, aspartic acid and proline. Product evidence is kept separate from experiments on a defined EDP sequence.
Research context
A product named in the originating-institute clinical-report collection. Experimental sequence, marketed formulation and clinical preparation must be checked separately.
- Working classification
- Peptide product / formulation research
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —Institute report; independent peer review not established
- Study methods
- —Randomization, blinding and product characterization unresolved
- Independent replication
- —Independent replication not established in this collection
- Source access
- —See source-specific abstracts, institute reports and explicit review scopes
- Safety evidence
- —Systematic safety assessment incomplete
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
View this preparation in the Khavinson evidence map ↗
Linked sources
Explore the research map and unresolved leads ↗
Crystagen — originating-institute clinical report
Marketed product / formulation not independently verified · Institute report / commercial reproduction
Originating institute; report reproduced in commercial collection · Reports on clinical studies of CYTOMAX and CYTOGEN products; PDF page 109
Human report located; design quality and independent confirmation remain unresolved.
- Population / setting
- 40 treated patients after radiation exposure; comparator size not transcribed
- What was checked
- Relevant report text checked in the 125-page PDF edition; not the chat’s unlocated 152-page edition.
Limitations & review scope
- Commercially distributed institute report; independent peer review, randomization and blinding not established.
- Product composition is not independently characterized here; do not equate a marketed formulation with a purified experimental sequence.
- Reported absence of harms does not establish safety.
Source checked 2026-09-30. This is a source-linked record, not a completed evidence review.